Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anna Pavlick, MD
NYU Clinical Cancer Center
Principal Investigator - Harriet Kluger, MD
Yale New Haven Hospital
Principal Investigator - Melissa Burgess, MD
University of Pittsburgh
Principal Investigator - Mohammed Milhem, MD
Univ of Iowa
Principal Investigator - Ravi Amaravadi, MD
Univ of Pennsylvania
Principal Investigator - Richard Carvajal, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Harriet Kluger
New Haven, Connecticut, United States
- Mohammed Milhem, Md
Iowa City, Iowa, United States
- Anna Pavlick, Md
New York, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Ravi Amaravadi, Md
Philadelphia, Pennsylvania, United States
- Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2015
- Primary completion
- 31 Mar 2016
- Completion
- 31 Mar 2016
- Last update posted
- 12 Oct 2017
- Registered enrollment
- 5
- Registry id
- NCT02230306
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.